Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal
After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.
You may also be interested in...
Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
Prosecutors' two-month probe into Hanmi Pharmaceutical has concluded without a big bang after they found the South Korean firm did not intentionally delay the disclosure of a licensee decision to end a cancer drug partnership, but several employees have nevertheless been arrested over improper information leakage.